{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T05:08:19Z","timestamp":1780376899497,"version":"3.54.1"},"reference-count":75,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Upper tract urothelial carcinoma (UTUC) presents a clinically important gap in urologic oncology: treatment intensity is determined before surgery, yet conventional preoperative risk stratification remains imperfect. Kidney-sparing surgery (KSS) is established for selected low-risk disease and is increasingly considered when renal preservation is clinically important, but safe selection depends on distinguishing technically manageable tumors from biologically unsuitable disease. Computed tomography urography (CTU), cytology, ureteroscopy, and ureteroscopic biopsy remain indispensable, although they describe anatomy and morphology more reliably than tumor biology. Urine-based liquid biopsy platforms, including DNA methylation, mutational, multiplex RNA, copy-number, and protein assays, appear most mature for noninvasive detection and preoperative triage. Plasma circulating tumor DNA (ctDNA), in contrast, appears more closely linked to biological upstaging, occult muscle-invasive or non-organ-confined disease, perioperative risk refinement, and molecular\u00a0residual disease surveillance. This review follows the KSS decision chain from patient selection to postoperative monitoring. We emphasize that current evidence supports liquid biopsy as an adjunctive, decision-enhancing layer rather than a replacement for imaging, ureteroscopy, pathology, or multidisciplinary judgment. Future studies should move beyond isolated sensitivity and specificity estimates and test whether biomarker-informed pathways improve treatment allocation, renal preservation, surveillance burden, and oncologic outcomes.<\/jats:p>","DOI":"10.3389\/fonc.2026.1844668","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:28:39Z","timestamp":1780374519000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Liquid biopsy-guided kidney-sparing management in upper tract urothelial carcinoma: from preoperative risk stratification to perioperative surveillance"],"prefix":"10.3389","volume":"16","author":[{"given":"Difei","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Urology, The Affiliated Yongchuan Hospital of Chongqing Medical University","place":["Chongqing, Yongchuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiarun","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Urology, The Affiliated Yongchuan Hospital of Chongqing Medical University","place":["Chongqing, Yongchuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, The Affiliated Yongchuan Hospital of Chongqing Medical University","place":["Chongqing, Yongchuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Urology, The Affiliated Yongchuan Hospital of Chongqing Medical University","place":["Chongqing, Yongchuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Qing","sequence":"additional","affiliation":[{"name":"Department of Urology, The Affiliated Yongchuan Hospital of Chongqing Medical University","place":["Chongqing, Yongchuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiamo","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, The Affiliated Yongchuan Hospital of Chongqing Medical University","place":["Chongqing, Yongchuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/MOU.0000000000001242","article-title":"Upper tract urothelial carcinoma: epidemiology, presentation, and high-risk endemic populations","volume":"35","author":"Clark","year":"2025","journal-title":"Curr Opin Urol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-016-1928-x","article-title":"Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)","volume":"35","author":"Soria","year":"2017","journal-title":"World J Urol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.21037\/tau.2019.11.22","article-title":"Epidemiology, clinical presentation, and evaluation of upper-tract urothelial carcinoma","volume":"9","author":"Petros","year":"2020","journal-title":"Transl Androl Urol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(05)67019-x","article-title":"Upper tract urothelial neoplasms: incidence and survival during the last 2 decades","volume":"164","author":"Munoz","year":"2000","journal-title":"J Urol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09675.x","article-title":"Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973\u20132005","volume":"107","author":"Raman","year":"2011","journal-title":"BJU Int"},{"key":"B7","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.euo.2020.11.005","article-title":"Incidence and survival rates of contemporary patients with invasive upper tract urothelial carcinoma","volume":"4","author":"Coll\u00e0 Ruvolo","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.eururo.2025.02.023","article-title":"European association of urology guidelines on upper urinary tract urothelial carcinoma: summary of the 2025 update","volume":"87","author":"Masson-Lecomte","year":"2025","journal-title":"Eur Urol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003480","article-title":"Diagnosis and management of non-metastatic upper tract urothelial carcinoma: AUA\/SUO guideline","volume":"209","author":"Coleman","year":"2023","journal-title":"J Urol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16061115","article-title":"Upper tract urothelial cancer: Guideline of guidelines","volume":"16","author":"Pandolfo","year":"2024","journal-title":"Cancers"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13216593","article-title":"Kidney-sparing surgery for upper tract urothelial carcinoma\u2014modalities, outcomes, and limitations","volume":"13","author":"Head","year":"2024","journal-title":"JCM"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2019.10.015","article-title":"Segmental ureterectomy for upper tract urothelial carcinoma: A systematic review and meta-analysis of comparative studies","volume":"18","author":"Veccia","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30147-9","article-title":"Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial","volume":"21","author":"Kleinmann","year":"2020","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003202","article-title":"Final results of a phase I trial of WST-11 (TOOKAD Soluble) vascular-targeted photodynamic therapy for upper tract urothelial carcinoma","volume":"209","author":"Yip","year":"2023","journal-title":"J Urol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1097\/MOU.0000000000001240","article-title":"Upper tract urothelial carcinoma: conservative management - intraluminal adjuvant therapy, and surveillance","volume":"35","author":"Lasmanovich","year":"2025","journal-title":"Curr Opin Urol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.21037\/tau.2019.12.25","article-title":"Perioperative complications and adverse sequelae of radical nephroureterectomy","volume":"9","author":"Levy","year":"2020","journal-title":"Transl Androl Urol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25073695","article-title":"Prognostic value of liquid-biopsy-based biomarkers in upper tract urothelial carcinoma","volume":"25","author":"Padull\u00e9s","year":"2024","journal-title":"IJMS"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/jcm15041612","article-title":"Urine-based biomarkers in the diagnosis of upper tract urothelial carcinoma: A systematic review and meta-analysis","volume":"15","author":"Xiao","year":"2026","journal-title":"JCM"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-023-00725-2","article-title":"Circulating and urinary tumour DNA in urothelial carcinoma \u2014 upper tract, lower tract and metastatic disease","volume":"20","author":"Rose","year":"2023","journal-title":"Nat Rev Urol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2020.06.024","article-title":"Diagnostic accuracy of ureteroscopic biopsy in predicting stage and grade at final pathology in upper tract urothelial carcinoma: Systematic review and meta-analysis","volume":"46","author":"Subiela","year":"2020","journal-title":"Eur J Surg Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2018.02.002","article-title":"Discordance between ureteroscopic biopsy and final pathology for upper tract urothelial carcinoma","volume":"199","author":"Margolin","year":"2018","journal-title":"J Urol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.03.005","article-title":"Large-scale prospective validation study of a multiplex RNA urine test for noninvasive detection of upper tract urothelial carcinoma","volume":"7","author":"Zhang","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15334","article-title":"Perioperative circulating tumor DNA enables the identification of patients with poor prognosis in upper tract urothelial carcinoma","volume":"113","author":"Nakano","year":"2022","journal-title":"Cancer Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.09.017","article-title":"Novel use of circulating tumor DNA to identify muscle-invasive and non\u2013organ-confined upper tract urothelial carcinoma","volume":"85","author":"Huelster","year":"2024","journal-title":"Eur Urol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/cas.16025","article-title":"Postoperative recurrence detection using individualized circulating tumor DNA in upper tract urothelial carcinoma","volume":"115","author":"Tamura","year":"2024","journal-title":"Cancer Sci"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"key":"B27","article-title":"Perioperative use of ctDNA to guide treatment for urothelial carcinoma: The future is now","volume":"10","author":"Stewart","year":"2024","journal-title":"Bladder Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/iju.70215","article-title":"Current status and future perspectives of molecular residual disease testing in genitourinary cancers","volume":"32","author":"Kato","year":"2025","journal-title":"Int J Urol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.eururo.2023.03.013","article-title":"European association of urology guidelines on upper urinary tract urothelial carcinoma: 2023 update","volume":"84","author":"Roupr\u00eat","year":"2023","journal-title":"Eur Urol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.21037\/tau-23-45","article-title":"Diagnosis, workup, and risk stratification of upper tract urothelial carcinoma","volume":"12","author":"Zganjar","year":"2023","journal-title":"Transl Androl Urol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/MOU.0000000000001248","article-title":"Comparison of surgical effectiveness: kidney sparing surgery for upper tract urothelial carcinoma","volume":"35","author":"Schuil","year":"2025","journal-title":"Curr Opin Urol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.ajur.2024.08.003","article-title":"Kidney-sparing approach for upper tract urothelial carcinoma: An update on current evidence","volume":"12","author":"Ko","year":"2025","journal-title":"Asian J Urol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.07.014","article-title":"Oncologic outcomes of kidney-sparing surgery versus radical nephroureterectomy for upper tract urothelial carcinoma: A systematic review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel","volume":"70","author":"Seisen","year":"2016","journal-title":"Eur Urol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000002350","article-title":"Durability of response to primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel: OLYMPUS trial final report","volume":"207","author":"Matin","year":"2022","journal-title":"J Urol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2019.02.004","article-title":"Endocavitary treatment for upper tract urothelial carcinoma: A meta-analysis of the current literature","volume":"37","author":"Foerster","year":"2019","journal-title":"Urologic Oncol Semin Original Investigations"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-012-0957-3","article-title":"Intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinomas: predictors and impact on subsequent oncological outcomes from a national multicenter study","volume":"31","author":"Xylinas","year":"2013","journal-title":"World J Urol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000001786","article-title":"Risk factors for intravesical recurrence after minimally invasive nephroureterectomy for upper tract urothelial cancer (ROBUUST Collaboration)","volume":"206","author":"Katims","year":"2021","journal-title":"J Urol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.urology.2016.04.030","article-title":"Diagnostic utility of selective upper tract urinary cytology: A systematic review and meta-analysis of the literature","volume":"96","author":"Potretzke","year":"2016","journal-title":"Urology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jasc.2020.06.011","article-title":"A review of urinary cytology in the setting of upper tract urothelial carcinoma","volume":"10","author":"Zhang","year":"2021","journal-title":"J Am Soc Cytopathology"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/cncy.22343","article-title":"A review of upper urinary tract cytology performance before and after the implementation of The Paris System","volume":"129","author":"Zhang","year":"2021","journal-title":"Cancer Cytopathol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajur.2022.08.003","article-title":"Diagnosing upper tract urothelial carcinoma: A review of the role of diagnostic ureteroscopy and novel developments over last two decades","volume":"11","author":"Gravestock","year":"2024","journal-title":"Asian J Urol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1080\/2090598X.2021.1883810","article-title":"Diagnostic ureteroscopy for upper tract urothelial carcinoma: friend or foe","volume":"19","author":"Territo","year":"2021","journal-title":"Arab J Urol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.humpath.2018.11.021","article-title":"Clinical utility and concordance of upper urinary tract cytology and biopsy in predicting clinicopathological features of upper urinary tract urothelial carcinoma","volume":"86","author":"Simon","year":"2019","journal-title":"Hum Pathol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16051002","article-title":"Overcoming understaging and undergrading in upper tract urothelial carcinoma. Comment on Ghoreifi et\u00a0al. Modern kidney-sparing management of upper tract urothelial carcinoma. Cancers 2023, 15, 4495","volume":"16","author":"Jue","year":"2024","journal-title":"Cancers"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s11934-024-01245-1","article-title":"Clinical implications of the molecular and genomic landscape of upper tract urothelial carcinoma","volume":"26","author":"Jaime-Casas","year":"2025","journal-title":"Curr Urol Rep"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.07.039","article-title":"Genomic characterization of upper tract urothelial carcinoma","volume":"68","author":"Sfakianos","year":"2015","journal-title":"Eur Urol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.ccell.2021.05.008","article-title":"Molecular classification and diagnostics of upper urinary tract urothelial carcinoma","volume":"39","author":"Fujii","year":"2021","journal-title":"Cancer Cell"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2020.12.007","article-title":"Genetic differences between bladder and upper urinary tract carcinoma: Implications for therapy","volume":"4","author":"Sfakianos","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003188","article-title":"A urine-based DNA methylation marker test to detect upper tract urothelial carcinoma: A prospective cohort study","volume":"209","author":"Ghoreifi","year":"2023","journal-title":"J Urol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01772-5","article-title":"Clinical validation of UroCAD test for upper tract urothelial carcinoma detection: results from a prospective multi-center study","volume":"19","author":"Yang","year":"2026","journal-title":"J Hematol Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-018-1237-x","article-title":"Fluorescence in situ hybridization in 1 mL of selective urine for the detection of upper tract urothelial carcinoma: a feasibility study","volume":"36","author":"Freund","year":"2019","journal-title":"Med Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15344","article-title":"Fluorescence in situ hybridization status of voided urine predicts invasive and high-grade upper tract urothelial carcinoma","volume":"8","author":"Su","year":"2017","journal-title":"Oncotarget"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqy170","article-title":"Diagnostic utility of UroVysion combined with conventional urinary cytology for urothelial carcinoma of the upper urinary tract","volume":"151","author":"Sassa","year":"2019","journal-title":"Am J Clin Pathol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14061520","article-title":"Non-invasive biomarkers in the diagnosis of upper urinary tract urothelial carcinoma\u2014a systematic review","volume":"14","author":"Bia\u0142ek","year":"2022","journal-title":"Cancers"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000002748","article-title":"DNA methylation urine biomarkers test in the diagnosis of upper tract urothelial carcinoma: results from a single-center prospective clinical trial","volume":"208","author":"Territo","year":"2022","journal-title":"J Urol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000001904","article-title":"DNA methylation urine test in the diagnosis of upper tract urothelial carcinoma: a systematic review and meta-analysis","volume":"111","author":"Ye","year":"2025","journal-title":"Int J Surg"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.23736\/S2724-6051.23.05488-5","article-title":"Prospective evaluation of the RT-PCR based urinary marker Bladder Epicheck\u00ae as a diagnostic tool in upper urinary tract tumor","volume":"76","author":"Palermo","year":"2024","journal-title":"Minerva Urol Nephrol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1186\/s12885-024-12913-3","article-title":"A urine-based liquid biopsy for detection of upper tract urothelial carcinoma: a self-matched study","volume":"24","author":"Wei","year":"2024","journal-title":"BMC Cancer"},{"key":"B59","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.clgc.2022.10.008","article-title":"DNA methylation architecture provides insight into the pathogenesis of upper tract urothelial carcinoma: a systematic review and meta-analysis","volume":"21","author":"Lin","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14000","article-title":"Diagnostic potential of TERT promoter and FGFR 3 mutations in urinary cell\u2010free DNA in upper tract urothelial carcinoma","volume":"110","author":"Hayashi","year":"2019","journal-title":"Cancer Sci"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.597486","article-title":"A urine-based liquid biopsy method for detection of upper tract urinary carcinoma","volume":"10","author":"Xu","year":"2021","journal-title":"Front Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14143537","article-title":"Urine cellular DNA point mutation and methylation for identifying upper tract urinary carcinoma","volume":"14","author":"Ouyang","year":"2022","journal-title":"Cancers"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000004803","article-title":"Diagnostic accuracy of the Oncuria-Detect multiplex immunoassay in detecting upper tract urothelial carcinoma","volume":"215","author":"Fujita","year":"2026","journal-title":"J Urol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlb.2025.100310","article-title":"Liquid biopsy: current advancements in clinical practice for bladder cancer","volume":"9","author":"Crocetto","year":"2025","journal-title":"J Liquid Biopsy"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01659","article-title":"Improved disease-free survival with adjuvant chemotherapy after nephroureterectomy for upper tract urothelial cancer: final results of the POUT trial","volume":"42","author":"Birtle","year":"2024","journal-title":"JCO"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.06.007","article-title":"Updated overall survival by circulating tumor DNA status from the phase 3 IMvigor010 trial: adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"85","author":"Powles","year":"2024","journal-title":"Eur Urol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-25-471912","article-title":"Current and future role of circulating DNA in the diagnosis and management of urothelial carcinoma","volume":"45","author":"Bellmunt","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1097\/MOU.0000000000000936","article-title":"Lynch syndrome in urological practice: diagnosis, therapeutic strategies, and screening for upper tract urothelial carcinoma","volume":"32","author":"Lonati","year":"2022","journal-title":"Curr Opin Urol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.urology.2022.02.006","article-title":"Immunohistochemical screening of upper tract urothelial carcinomas for Lynch syndrome diagnostics: a systematic review","volume":"165","author":"Rasmussen","year":"2022","journal-title":"Urology"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100883","article-title":"Inherited mutations in Chinese patients with upper tract urothelial carcinoma","volume":"4","author":"Wu","year":"2023","journal-title":"Cell Rep Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11195827","article-title":"Urinary comprehensive genomic profiling correlates urothelial carcinoma mutations with clinical risk and efficacy of intervention","volume":"11","author":"Bicocca","year":"2022","journal-title":"J Clin Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3390\/diseases12090219","article-title":"The simultaneous use of Bladder EpiCheck and urinary cytology can improve the sensitivity and specificity of diagnostic follow-up of urothelial lesions: up-to-date data from a multi-institutional cohort","volume":"12","author":"Pepe","year":"2024","journal-title":"Diseases"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1002\/cncy.22657","article-title":"DNA methylation analysis in urinary samples: a useful method to predict the risk of neoplastic recurrence in patients with urothelial carcinoma of the bladder in the high-risk group","volume":"131","author":"Pierconti","year":"2023","journal-title":"Cancer Cytopathol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25126750","article-title":"Programmed cell death ligand 1 (PD-L1) immunohistochemical expression in advanced urothelial bladder carcinoma: an updated review with clinical and pathological implications","volume":"25","author":"Germana","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-014-1311-8","article-title":"Influence of preoperative factors on the oncologic outcome for upper urinary tract urothelial carcinoma after radical nephroureterectomy","volume":"33","author":"Hurel","year":"2015","journal-title":"World J Urol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1844668\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:28:40Z","timestamp":1780374520000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1844668\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":75,"alternative-id":["10.3389\/fonc.2026.1844668"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1844668","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"article-number":"1844668"}}